Table 3 Comparison of baseline characteristics and treatment of patients witht different genetic backgrounds

Age at diagnosis, [years, median (range)]

6.37 (0.25−13)

7.8 (2–12)

4.8(0.75−11)

Diagnosis, no./total (%)

 RCC

4 (50%)

4 (80%)

7 (63.6%)

 Advanced MDS

4 (50%)

1 (20%)

4 (36.4%)

Hematological characteristics

 Hb level,median (range)

69 (44–101)

82 (54–100)

83 (46–125)

 PLT count,median (range)

53 (13–165)

45 (22–80)

62 (10–263)

 NE count, median (range)

1.6 (0.39–5.08)

1.7 (0.83–2.82)

0.98 (0.13–1.95)

 TD at diagnosis

6 (75%)

2 (40%)

2 (18.2%)

Treatment at diagnosis, no./total (%)

 Watch&wait / Support therapy

3 (50%)

2 (40%)

5 (45.4%)_

 IST (CsA)

1 (12.5%)

2 (40%)

4 (36.4%)

 HSCT

4 (50%)

1 (20%)

2 (18.2%)

Response, no./total (%)

 Hematological improvement(HI)

4 (50%)

2 (40%)

5 (45.4%)

 Stable disease (SD)

1(12.5%)

2 (40%)

5 (45.4%)

 Disease progression (PD)

3 (37.5%)

1 (20%)

1 (9.1%)

Outcomes, no./total (%)

 Survivl

6 (75%)

4 (80%)

10 (90.9%)

 Death

2 (25%)

1 (20%)

1 (9.1%)